Another Agent Raises Hopes for Obstructive HCM in Early Study Another Agent Raises Hopes for Obstructive HCM in Early Study

Hemodynamics improved significantly for patients with obstructive hypertrophic cardiomyopathy who took aficamten, the second myosin inhibitor to reach clinical trials, in a small randomized study.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news